These results demonstrate the importance of PKCβII in chronic lymphocytic leukemia-like disease progression and suggest a role for PKCα subversion in creating permissive conditions for leukemogenesis.
Introduction:
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world and is characterized by the presence of long-lived mature B cells with the distinct phenotype CD19 + CD5 + CD23 + IgM lo FMC7 -. 1 Although deregulation of anti-apoptotic Bcl-2 family members indicated that CLL developed due to inappropriate accumulation of monoclonal B cells, 1,2 assessment of cell turnover revealed that CLL cells also undergo enhanced cell division within proliferation centers of lymphoid organs. This occurs through CLL cell interaction with the stromal niche, antigen and co-stimulation by activated CD4 + T lymphocytes expressing CD40
ligand (CD40L), and interleukin 4 (IL4). [3] [4] [5] Therefore, CLL is a dynamic disease with significant rates of proliferation and death that requires complex in vitro and in vivo disease model systems to gain a fundamental understanding of the disease and design suitable therapies.
Clinically, CLL is a heterogeneous disease that can follow an indolent or aggressive course. Over the past decade it has been established that two major prognostic subtypes of CLL can be defined by the mutational status of the variable region of immunoglobulin heavy chain gene (IgV H ). Favorable outcomes are associated with expression of mutated (M) IgV H genes, while cases harboring unmutated (UM) IgV H genes, which can also express the tyrosine kinase, zetaassociated protein 70 (ZAP-70) and CD38, display more aggressive disease and frequently require therapeutic intervention. 6, 7 ZAP-70 expression correlates highly with unmutated IgV H . 8 While a wealth of research into the biology of CLL has shown the importance of a number of proteins, particularly in those assisting in chemoresistance (eg., Mcl-1, absence of p53), no single genetic event has been linked to the initiation of CLL. Due to the heterogeneity within CLL, it is likely that a number of in vitro and in vivo models will be required to elucidate different aspects of the disease and gain a fuller understanding of the initiation, maintenance and progression of CLL. We previously demonstrated that retroviral-transduction of hematopoietic progenitor cells (HPCs) with a kinase dead PKCα construct (PKCα-KR) and subsequent culture either in an in vitro B cell generation culture (OP9 co-culture) or in vivo, resulted in the generation of CLL-like cells and disease, 9 indicating that modulation of PKCα function may play a role in CLL cell development. In the present study, we further characterize the In vitro or in vivo B cell generation. HPCs isolated from E14 FL were prepared and retrovirally-transduced as described previously. 13 Retrovirally-transduced HPCs were cultured on a layer of OP9 cells for B cell development in the presence of IL-7
(Peprotech EC Ltd., London, UK), or adoptively transferred as described previously. 13 Mice were sacrificed between 5 to 8 wk post-injection and the bone marrow (BM), spleen, lymph node (LN) and blood were collected for analyses.
Flow Cytometric Analysis. Antibodies were purchased from BD Biosciences (Oxford, UK). Biotin-conjugated antibodies were detected by streptavidin-pacific blue (Invitrogen, Paisley UK). Single cell suspensions were stained as described previously. 13 The cells were acquired on a FACSCantoII (BD Biosciences) using the Figure 1A Supporting this, aicda expression, which has been associated with increased CLL cell proliferation, 16, 17 was significantly increased in GFP + CD19 + cells expressing PKCα-KR at the later stages of culture compared to MIEV-expressing cells ( Figure 3F ).
We previously demonstrated that PKCα-KR-transduced cells exhibited reduced PKC activity during the early stages of the OP9 co-culture, as expected ( Figure 4A -left) 9 . However we observed an elevation in PKC activity later in the co- Taken together, our CLL-like cells exhibit a higher expression of markers associated with adverse outcome in CLL patients and possess an enhanced proliferation capacity, likely due to elevated mTor signaling upon PKCα subversion.
This, coupled with the finding that PKCα expression is reduced in the majority of CLL patient samples assessed, indicates that our CLL-like disease model is a translationally-relevant model for the progressive human disease.
PKCβ selective inhibitors inhibit CLL-like cell proliferation in vitro and in vivo
To determine whether PKCβ plays an important role in driving proliferation and cell survival in our mouse CLL-like disease model in vitro, CLL-like cells were treated with the PKCβ selective inhibitor, enzastaurin. PKCβ has previously been shown to phosphorylate and inhibit GSK3β. 20 Therefore to test the selectivity of enzastaurin for
PKCβ-mediated signals, we assessed the phosphorylation status of GSK3β. PKCα-KR-expressing cells from late co-cultures exhibited increased phospho-GSK3β S9 , which was abrogated by enzastaurin treatment (20 µM; Figure 5A ). Enzastaurin treatment induced a selective and significant elevation in apoptosis above background Figure 5D ). In addition, and supporting the data presented in Figure 3D , PKCα-KR-expressing cells exhibited a significantly higher proliferation rate than MIEV cells in untreated cultures, and treatment of these cells with enzastaurin reduced their proliferation rate to that of MIEV cells ( Figure 5D ). These results demonstrate that enzastaurin selectively inhibited cell cycle progression and proliferation in CLL-like cells in vitro.
To test the efficacy of enzastaurin to inhibit proliferation of CLL-like cells in vivo, mice were treated with enzastaurin twice a day for up to three weeks, after 
Discussion:
We previously established that subversion of PKCα confers a CLL-like phenotype to B lineage cells both in vitro and in vivo. 9 We now demonstrate that PKCα-KR- triplicates. p values were generated using the student's unpaired t-test * p<0.05, ** p<0.005, *** p<0.001. 
